This article is more than 5 years old. Information may no longer be current.
Intravitreal bevacizumab may be effective in CNV management
Click Here to Manage Email Alerts
Monthly injections of bevacizumab decreased central retinal thickness and improved vision in a study of patients with choroidal neovascularization due to age-related macular degeneration, according to a study.
Ziad F. Bashshur, MD, and colleagues at the American University of Beirut reviewed data from 17 eyes of 17 patients with subfoveal choroidal neovascularization (CNV) due to AMD. Patients were given a 2.5 mg injection of bevacizumab at baseline, followed by two more injections at 4-week intervals.
Mean BCVA at baseline was 20/252 and central retinal thickness was 362 µm. At the 4-week follow-up, the researchers reported that mean and median BCVA improved to 20/105 and mean and median central retinal thickness decreased to 279 µm and 282 µm, respectively. At 12 weeks, mean BCVA was 20/76 and median BCVA was 20/50 and both mean and median central retinal thickness decreased to 211 µm.
The researchers also reported total resolution of subretinal fluid in 13 of 17 eyes (76%), and that four eyes had BCVA better than 20/50.
Long-term studies are needed to determine the ideal dose and safety and efficacy of intravitreal bevacizumab, the researchers said.
This study was published in the July issue of the American Journal of Ophthalmology.